Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BLTE Stock Forecast 2026-2027
$143.35
Current Price
$5.75B
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to BLTE Price Targets
+85.6%
To High Target of $266.00
+39.9%
To Median Target of $200.50
+29.1%
To Low Target of $185.00
BLTE Price Momentum
-0.6%
1 Week Change
-8.2%
1 Month Change
+140.2%
1 Year Change
-10.4%
Year-to-Date Change
-28.3%
From 52W High of $200.00
+155.5%
From 52W Low of $56.10
📊 TOP ANALYST CALLS
Did BLTE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Belite Bio is one of their latest high-conviction picks.
Latest BLTE Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, BLTE has a bullish consensus with a median price target of $200.50 (ranging from $185.00 to $266.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $143.35, the median forecast implies a 39.9% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BLTE Analyst Ratings
8
Buy
0
Hold
0
Sell
BLTE Price Target Range
Low
$185.00
Average
$200.50
High
$266.00
Current: $143.35
Latest BLTE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BLTE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 26, 2026 | Mizuho | Graig Suvannavejh | Outperform | Maintains | $215.00 |
| May 21, 2026 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $200.00 |
| Apr 22, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 13, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 3, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 3, 2026 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Mar 3, 2026 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Jan 28, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 26, 2026 | B of A Securities | Buy | Initiates | $N/A | |
| Jan 6, 2026 | Morgan Stanley | Overweight | Initiates | $N/A | |
| Dec 2, 2025 | Mizuho | Outperform | Upgrade | $N/A | |
| Dec 1, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 24, 2025 | Cantor Fitzgerald | Steve Seedhouse | Overweight | Assumes | $154.00 |
| Nov 20, 2025 | Mizuho | Neutral | Initiates | $N/A | |
| Oct 31, 2025 | Benchmark | Buy | Maintains | $N/A | |
| Sep 15, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jul 3, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 15, 2025 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| May 15, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 26, 2025 | Benchmark | Buy | Reiterates | $N/A |
Belite Bio, Inc. (BLTE) Competitors
The following stocks are similar to Belite Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Belite Bio, Inc. (BLTE) Financial Data
Belite Bio, Inc. has a market capitalization of $5.75B with a P/E ratio of -61.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -18.9%.
Valuation Metrics
Market Cap
$5.75B
Enterprise Value
$5.39B
P/E Ratio
-61.8x
PEG Ratio
-1.2x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
N/A
Current Ratio
33.7x
Debt/Equity
0.0x
ROE
-18.9%
ROA
-13.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Belite Bio, Inc. (BLTE) Business Model
About Belite Bio, Inc.
What They Do
Develops oral therapeutics for retinal diseases.
Business Model
Belite Bio, Inc. operates as a clinical-stage biopharmaceutical company, focusing on developing innovative oral therapies aimed at treating degenerative retinal diseases. The company generates revenue primarily through the development and commercialization of its drug candidates, such as Tinlarebant, which is currently in phase 3 clinical trials. Regulatory designations like Breakthrough Therapy and Orphan Drug status enhance its market potential and accelerate the development process.
Additional Information
Founded in 2016 and based in San Diego, California, Belite Bio has received several regulatory approvals, indicating strong potential for its lead therapies. In addition to its retinal disease treatments, the company is also developing LBS-009 for liver diseases, diversifying its pipeline and addressing multiple significant medical needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
41
CEO
Dr. Yu-Hsin Lin M.B.A., Ph.D.
Country
United States
IPO Year
2022
Website
www.belitebio.comBelite Bio, Inc. (BLTE) Latest News & Analysis
Latest News
Quick Summary
Belite Bio, Inc (NASDAQ: BLTE) will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 4:00 pm ET. Webcast available online.
Why It Matters
Belite Bio's participation in a major healthcare conference highlights its visibility and credibility, potentially attracting investor interest and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Belite Bio Q1 Earnings Call Highlights
17 days ago
Quick Summary
Belite Bio (NASDAQ: BLTE) has started a rolling New Drug Application for Tinlarebant to treat Stargardt disease and is expediting preparations for a possible commercial launch.
Why It Matters
Belite Bio's NDA submission for Tinlarebant signals progress in treatment for Stargardt disease, potentially increasing its market value and attracting investor interest in the biotech sector.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Belite Bio, Inc (BLTE) held its Q1 2026 earnings call, discussing financial performance and strategic updates. Detailed insights on revenue, expenses, and future outlook were provided.
Why It Matters
Belite Bio's Q1 2026 earnings report reveals financial health and growth potential, influencing stock performance and investment decisions in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
17 days ago
Quick Summary
Belite Bio (NASDAQ: BLTE) reported its unaudited Q1 2026 financial results, focusing on novel therapeutics for degenerative retinal diseases with unmet medical needs.
Why It Matters
Belite Bio's quarterly financial results and business update signal progress in drug development, impacting investor sentiment and potential future valuations in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
19 days ago
Quick Summary
Belite Bio, Inc. announced that Swissmedic has granted orphan drug status to its lead candidate, tinlarebant, for treating Stargardt disease, a rare retinal disorder.
Why It Matters
The orphan drug status for tinlarebant may enhance Belite Bio's market position, potentially increasing its valuation and attracting investment due to reduced competition and exclusive market rights.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Belite Bio, Inc. (NASDAQ: BLTE) will present positive topline results from its Phase 3 DRAGON trial for tinlarebant, targeting Stargardt disease, at Retina China 2026 in Nanjing, May 21-23.
Why It Matters
Belite Bio's positive Phase 3 trial results and upcoming presentation may boost investor confidence, signaling potential for regulatory approval and market success in treating Stargardt disease.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About BLTE Stock
What is Belite Bio, Inc.'s (BLTE) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Belite Bio, Inc. (BLTE) has a median price target of $200.50. The highest price target is $266.00 and the lowest is $185.00.
Is BLTE stock a good investment in 2026?
According to current analyst ratings, BLTE has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $143.35. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BLTE stock?
Wall Street analysts predict BLTE stock could reach $200.50 in the next 12 months. This represents a 39.9% increase from the current price of $143.35. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Belite Bio, Inc.'s business model?
Belite Bio, Inc. operates as a clinical-stage biopharmaceutical company, focusing on developing innovative oral therapies aimed at treating degenerative retinal diseases. The company generates revenue primarily through the development and commercialization of its drug candidates, such as Tinlarebant, which is currently in phase 3 clinical trials. Regulatory designations like Breakthrough Therapy and Orphan Drug status enhance its market potential and accelerate the development process.
What is the highest forecasted price for BLTE Belite Bio, Inc.?
The highest price target for BLTE is $266.00 from at , which represents a 85.6% increase from the current price of $143.35.
What is the lowest forecasted price for BLTE Belite Bio, Inc.?
The lowest price target for BLTE is $185.00 from at , which represents a 29.1% increase from the current price of $143.35.
What is the overall BLTE consensus from analysts for Belite Bio, Inc.?
The overall analyst consensus for BLTE is bullish. Out of 4 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $200.50.
How accurate are BLTE stock price projections?
Stock price projections, including those for Belite Bio, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 4:07 PM UTC